Two financings signaled investor appetite for biologically novel approaches to immune and brain diseases. Nilo Therapeutics launched with $101 million in Series A funding to develop therapies that harness neural circuits to restore immune homeostasis; the company was founded by leaders in neuro‑immunology and backed by The Column Group, DCVC Bio, Lux and others. Separately, Gate Bioscience raised $65 million to advance its “molecular gate” small‑molecule protein degraders toward first‑in‑human testing. Gate targets unconventional degradation modalities for immune and CNS indications. Both financings reflect investor interest in platform medicines that combine novel biology (neural‑immune interfaces, targeted degradation) with potential broad disease applicability. Clarification: molecular gate degraders are a variant of targeted protein degradation that exploit new chemistries or E3 ligase engagements to remove disease drivers rather than inhibit them.